|
|
Volumn 102, Issue 9, 2013, Pages 3082-3088
|
|
A commentary on transdermal drug delivery systems in clinical trials
|
|
Author keywords
Clinical trials; Drug delivery systems; Skin; Transdermal; Transdermal drug delivery
|
|
Indexed keywords
BUPRENORPHINE;
CLONIDINE;
ESTRADIOL;
ETHINYLESTRADIOL;
FENTANYL;
GRANISETRON;
METHYLPHENIDATE;
NICOTINE;
NITRATE;
NORELGESTROMIN;
NORETHISTERONE ACETATE;
OXYBUTYNIN;
RIVASTIGMINE;
ROTIGOTINE;
SCOPOLAMINE;
SELEGILINE;
TESTOSTERONE;
CLINICAL TRIAL (TOPIC);
DRUG INDICATION;
DRUG INDUSTRY;
DRUG MARKETING;
FOOD AND DRUG ADMINISTRATION;
IONTOPHORESIS;
NOTE;
PHASE 3 CLINICAL TRIAL (TOPIC);
PHASE 4 CLINICAL TRIAL (TOPIC);
PHYSICAL CHEMISTRY;
TRANSDERMAL DRUG ADMINISTRATION;
CLINICAL TRIALS;
DRUG DELIVERY SYSTEMS;
SKIN;
TRANSDERMAL;
TRANSDERMAL DRUG DELIVERY;
ADMINISTRATION, CUTANEOUS;
CLINICAL TRIALS AS TOPIC;
DRUG DELIVERY SYSTEMS;
HUMANS;
PHARMACEUTICAL PREPARATIONS;
|
|
EID: 84881615653
PISSN: 00223549
EISSN: 15206017
Source Type: Journal
DOI: 10.1002/jps.23490 Document Type: Article |
|
Times cited : (22)
|
|
References (7)
|
